Angus councillors have given GlaxoSmithKline the green light to invest £25 million in their Montrose operation.
A new Active Pharmaceutical Ingredients plant is expected to provide an additional 25 jobs in a state-of-the-art facility at the Cobden Street site, which currently employs around 100 people.
The plant would work round-the-clock to produce ‘new chemical entities’ for the worldwide operations of the pharmaceutical giant.
Plans were announced almost a year ago by the president for global manufacturing and supply for GSK, Roger Connor, who said at the time: “This shows the good work that is being done in Montrose that we made the decision to invest the money into the site. It should be seen as a vote of confidence in the skills, standards and drive of the people who work here.”
Councillor David May welcomes the boost it would bring to the area and said it is “good news for Montrose and Angus as a whole.”
The development standards committee were given details of the three-storey production plant, on a 900 square metres footprint, which is to be built to the south of the GSK complex, re-using a brownfield site.
It will have the capacity to produce around 1,500kg of pharmaceutical ingredients every year, to be distributed globally and used in the production of new medicines, including treatments for cancer and respiratory problems.
There were no objections submitted in respect of the plan and the environmental statement by GSK, attached to the bid, indicated there would be no significant air quality or traffic impact if the development is built.
Scottish Natural Heritage (SNH) said it was unlikely there would be any effect on the Montrose Basin, which has Special Protection and Site of Special Scientific Interest (SSSI) status.
SNH informed councillors: “SNH considers there are sufficient controls in place to be confident that there would be no significant effect on the natural heritage designations close to the site.”